This hypothesis would, in fact, be consistent with the observation that significant toxicity was observed in a human clinical trial of a 90Y-labelled mini-gastrin peptide for radiotherapy of medullary thyroid cancers [36]. The gene discussed is GAST; the disease is medullary thyroid gland carcinoma.